Riskpilot← Back to searchSign inGet full accessCHLOPETHAN A/S
A/SActiveCVR 25732766Topstykket 12Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 2000— employees
Revenue 2024
DKK 36K
-345% vs 2023
EBITDA margin
100.0%
+263% vs 2023
Equity ratio
13.8%
Financial strength
Net profit 2024
DKK 560K
+113% vs 2023
| Revenue | DKK 36K | -345% |
| EBITDA | DKK 36K | +263% |
| Net profit | DKK 560K | +113% |
| Total assets | DKK 13,1M | +38% |
| Equity | DKK 1,8M | +45% |
| Employees | — | — |
Legal name
CHLOPETHAN A/S
CVR number
25732766
Legal form
Aktieselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
20. november 2000
Share capital
DKK 2.500.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af formanden for bestyrelsen i forening med et andet bestyrelsesmedlem eller af direktøren i forening med et medlem af bestyrelsen eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at eje kapitalandele og værdipapirer samt anden dermed beslægtet virksomhed.
Address
Topstykket 12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -11 | -17 | -11 | -12 | -12 | -12 | -13 | -12 | -11 | -16 | -15 | 36 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -11 | -17 | -11 | -12 | -12 | -12 | -13 | -911 | -60 | -23 | -22 | 36 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -11 | -17 | -11 | -12 | -12 | -12 | -13 | -911 | -60 | -23 | -22 | 36 |
| Net financials | 122 | 38 | 304 | 842 | -998 | -2.862 | -3.713 | -18.584 | -10.829 | -6.021 | -4.425 | 524 |
| Profit before tax | 112 | 93 | 292 | 965 | -987 | -2.761 | -3.501 | -19.495 | -10.382 | -6.044 | -4.447 | 560 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 112 | 93 | 292 | 965 | -987 | -2.761 | -3.501 | -19.495 | -10.382 | -6.044 | -4.447 | 560 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11.168 | 11.665 | 12.375 | 13.775 | 13.241 | 10.726 | 7.343 | 2.941 | 7.210 | 10.669 | 9.474 | 13.076 |
| Equity | 1.359 | 1.452 | 1.744 | 2.709 | 1.722 | -1.039 | -4.539 | 2.921 | 1.250 | 1.250 | 1.250 | 1.810 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 9.809 | 10.213 | 10.631 | 11.066 | 11.519 | 11.765 | 11.882 | 20 | 5.960 | 9.419 | 8.224 | 11.266 |
| Total debt | 9.809 | 10.213 | 10.631 | 11.066 | 11.519 | 11.765 | 11.882 | 20 | 5.960 | 9.419 | 8.224 | 11.266 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20132024
Equity ratio
13.8%
This company
38.2%
Market median
-64% vs market
20132024
Return on equity
30.9%
This company
18.4%
Market median
+68% vs market
20132024
Net profit margin
1568.1%
This company
8.1%
Market median
+19259% vs market
20132024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20132024
Debt / equity
6.22×
This company
0.62×
Market median
-903% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PB Management | Management | 2000 | — | — |
BL Audit | Audit | 2007 | — | — |
AB Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
HA Audit | Audit | 2000 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2026 | — | — | |
| Chairman | 2010 | — | — | |
| Board of Directors | 2001 | — | — | |
| Chairman | 2026 | — | — | |
| Chairman | 2009 | — | — | |
| Board of Directors | 2000 | — | — | |
| Chairman | 2000 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2008 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CHLOPETHAN A/S 
SCANPHARM A/SBoard members of CHLOPETHAN A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Preben Bang Henriksen | Management | 0 companies |
| Bent Lind Kofoed | Audit | 0 companies |
| Andreas Bjørn Jensen | Chief Executive Officer | 0 companies |
| Harry Aamann | Audit | 0 companies |
| Hanne Bjørn Jensen | Board of Directors | 0 companies |
| Holger Carsten Hansen | Chairman | 0 companies |
| Peter Bjørn Jensen | Board of Directors | 0 companies |
| Janus Doré Pagh | Chairman | 0 companies |
| Jens Terkel Lund-Nielsen | Chairman | 0 companies |
| Lone Mai Henriksen | Board of Directors | 0 companies |
| Stephan Muurholm | Chairman | 0 companies |